Financial Data and Key Metrics Changes - Q4 revenues grew by 23% year-over-year, totaling $8.8 million, while full-year revenues reached $33.6 million, representing an 18% increase [13][37] - Gross margins for Q4 were 62.9%, a 260 basis point improvement from the previous year, and full-year gross margins were 63.4%, reflecting a 480 basis point improvement [39][40] - The year-end cash balance was $9.6 million, exceeding expectations, with positive cash flow generated in Q4 [15][41] Business Line Data and Key Metrics Changes - Domestic core revenues increased by 20% in Q4 and 12% for the full year, driven by strong pump and consumable volume growth [35][38] - International core revenues grew by 14% in Q4 and 32% for the full year, supported by market penetration and geographic expansion [36][38] - Novel therapies revenues reached $700,000 in Q4, marking a 122% increase, and full-year revenues were $2.4 million, a 62% growth [37][39] Market Data and Key Metrics Changes - The U.S. SCIg market grew approximately 10% in 2024, marking the eighth consecutive quarter of year-over-year growth [17] - The international SCIg market also showed strong growth, with KORU entering new geographies in the Middle East, North Africa, and Eastern Europe [20][21] - The overall large-volume subcutaneous market is rapidly expanding, with over 18 large-volume drugs in development [11] Company Strategy and Development Direction - KORU Medical aims to become a global leader in large-volume subcutaneous drug delivery, focusing on expanding its market share in both domestic and international markets [9][12] - The company is transitioning its Novel Therapies segment to Pharma Services and Clinical Trials to better reflect its business model [24][46] - KORU plans to launch three new products in 2025, enhancing patient comfort and convenience [53][56] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining mid-teen growth rates in recurring revenue, driven by increased market share and new product launches [27][28] - The company anticipates operational cash flow positivity for the full year of 2025, with revenue guidance set between $38 million and $39 million [16][50] - Management noted potential supply disruptions from FDA announcements are expected to be short-term and manageable [25] Other Important Information - The company has approximately 49,000 patients, with 75% of revenues coming from recurring sources, indicating a strong recurring revenue base [26] - KORU holds about 10% share of a $60 million o-US SCIg market, indicating significant growth potential [28] Q&A Session Summary Question: Can you break down the 2025 guidance for domestic and international growth? - Management expects domestic revenue growth between 10% and 15% and international growth over 20%, with novel therapies contributing $2 million to $3 million [62] Question: What drives the above-market growth in 2025? - Growth will be driven by new geographies, increased market share, and new customer acquisitions, particularly in the international space [64][66] Question: What is the status of the oncology opportunity? - The company is focused on market assessment, reimbursement strategies, and establishing distribution partnerships for the oncology product [70] Question: Can you elaborate on the e-pump opportunity? - The e-pump market is seen as a significant growth driver, with KORU currently holding over 10% market share and plans for further penetration [82] Question: How do you view gross margin expansion with the new product portfolio? - The new consumables launch is expected to drive efficiencies and potentially increase gross margins to over 65% in the long term [85]

Urgent.ly (ULY) Q4 2024 Earnings Call March 12, 2025 10:32 PM ET Company Participants Jenny Mitchell - VP - Finance Strategy & IRMatthew Booth - President & CEOTim Huffmyer - CFO Conference Call Participants James McIlree - Senior Equity Research Analyst Operator Good afternoon, and welcome to Urgent Lease Fourth Quarter and Full Year twenty twenty four Conference Call. As a reminder, today's call is being recorded and your participation implies consent to such recording. At this time, all participants are ...

Assertio (ASRT) Q4 2024 Earnings Call March 12, 2025 10:32 PM ET Company Participants Matthew Kreps - Managing DirectorBrendan O’Grady - CEOAjay Patel - EVP & CFORaghuram Selvaraju - Managing Director, Healthcare Equity Research Conference Call Participants Jim Sidoti - AnalystThomas Flaten - Senior Research AnalystNaz Rahman - AnalystScott Henry - Managing Director & Senior Research Analyst Operator Thank you for standing by. My name is Eric, and I'll be your conference operator today. At this time, I woul ...

Eduardo Galvao Welcome to CI&T Earnings Call for the Fourth Quarter and Full Year of 2024. I am Eduardo Galvao, Director of Investor Relations at CI&T. Joining me today are Cesar Gon, our Founder and CEO; Bruno Guicardi, Founder and President for North America and Europe; and Stanley Rodrigues, our CFO. This event is being recorded and all participants will be in a listen-only mode during the Company's presentation. After that, there will be a Q&A session. [Operator Instructions] The presentation is availab ...

AudioEye (AEYE) Q4 2024 Earnings Call March 12, 2025 10:12 PM ET Company Participants David Moradi - Chief Executive OfficerKelly Georgevich - Chief Financial Officer Conference Call Participants Joshua Reilly - Senior AnalystZach Cummins - Senior Research AnalystRichard Baldry - MD & Senior Research AnalystGeorge Sutton - Senior Research AnalystScott Buck - Managing Director & Senior Technology Analyst Operator Good afternoon, and welcome to AudioEye's Fourth Quarter and Full Year twenty twenty four Earnin ...

ContextLogic (LOGC) Q4 2024 Earnings Call March 12, 2025 10:10 PM ET Company Participants Ted Goldthorpe - ChairpersonRishi Bajaj - Chairperson & CEO Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to today's call announcing the strategic investment in ContextLogic by BC Partners. At this time, all participants are in listen only mode and there will not be a question and answer section at the conclusion of today's call. However, a recording and transcript will be made a ...

Financial Data and Key Metrics Changes - For the full year 2024, the company reported net revenue of $334 million and adjusted EBITDA of $12.3 million, both exceeding guidance [9] - Fourth quarter revenue was $83.5 million, representing a 13.8% year-over-year decline [26] - Gross profit for Q4 was $52.3 million, compared to $45.7 million in the prior year, with adjusted gross margin improving to 67.1% from 54.6% [32] Business Line Data and Key Metrics Changes - Consumable sales for Q4 totaled $56.7 million, an 8.7% increase year-over-year, with full year consumable sales reaching $208.9 million compared to $191.4 million in 2023 [29] - Non-Syndeo device sales represented 29% of total systems sold in Q4, up from 21% in the prior year [28] - Total units sold in Q4 were 1,087, down from 1,551 units sold in Q4 2023 [28] Market Data and Key Metrics Changes - In the Americas, Q4 revenue was down 3.9%, while APAC and EMEA saw declines of 50.5% and 8.3% respectively [30] - In APAC, China accounted for $23.9 million of the region's revenue, reflecting a 56.4% year-over-year decline [30] - The decline in China was attributed to a 70.2% drop in system sales and an 8.3% decrease in consumables revenue [31] Company Strategy and Development Direction - The company identified three transformation priorities: sales execution, operational excellence, and financial discipline [11] - A new commercial leadership team has been established to drive device and consumable sales, increasing utilization and deepening provider relationships [14] - The company is transitioning its direct business in China to a third-party distributor model to capture market potential while maintaining a capital-light approach [17] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing macroeconomic uncertainty and industry headwinds but expressed confidence in the company's strategic direction [23] - The company expects full year 2025 sales between $270 million to $300 million, with adjusted EBITDA of $10 million to $25 million [37] - Management emphasized the importance of driving long-term shareholder value through strong sales execution and operational efficiency [39] Other Important Information - The company reduced operating expenses by over $30 million year-over-year, demonstrating a commitment to financial discipline [10] - The Hydralock HA Booster was launched in Q3 2024, marking the most successful Hydrafacial branded booster launch to date [19] - The company ended Q4 with approximately $370 million in cash and projected capital expenditures of $10 million to $15 million for 2025 [36][38] Q&A Session Summary Question: What is the outlook for delivery systems given macroeconomic conditions? - Management noted that providers are taking longer to make purchasing decisions due to macro uncertainty and high interest rates, impacting sales [44] Question: How is consumer demand for consumables expected to trend in 2025? - Management indicated consistent growth in consumables, with macro trends favoring continued demand [48][50] Question: What improvements have been made regarding machine reliability? - Management reported significant improvements in manufacturing quality and customer service, addressing minor technical issues promptly [57] Question: What is the strategy for the distributor model in China? - Management explained that the decision to move to a distributor model was based on the need for focused investment and expertise in the Chinese market [102] Question: How will the company manage operating expenses in 2025? - Management expects to maintain discipline in operating expenses while leveraging improvements in gross margins [135] Question: What is the expected cash flow situation for 2025? - Management anticipates being cash neutral throughout the year, with a typical use of cash in the first half transitioning to a source of cash in the second half [136]

Financial Data and Key Metrics Changes - Total net sales for Q4 2024 were $147.3 million, a decrease of 14.9% compared to Q4 2023 [11] - Comparable net sales decreased by 11.2% for the 13-week period ended February 1, 2025 [12] - Gross margin was 26% of net sales, down from 27% in the previous year [13] - Net loss was $13.7 million or $0.45 per share, compared to a net loss of $20.6 million or $0.69 per share in the previous year [15] Business Line Data and Key Metrics Changes - Physical store net sales increased by 13.7% but decreased by 9.8% on a comparable basis [12] - E-commerce net sales decreased by 17.8%, representing 26.5% of total net sales [13] Market Data and Key Metrics Changes - The company ended the fiscal year with 240 total stores, a net decrease of eight stores compared to the end of fiscal 2023 [12] - Total inventories were 9.5% higher than at the end of fiscal 2023, but as of March 1, 2025, inventories were 6.1% below last year's level [16] Company Strategy and Development Direction - The company is focusing on reducing inventory commitments and improving product margins for fiscal 2025 [9] - Significant expense reductions are targeted through careful management of store leases and operational costs [11] - The company plans to continue investing in marketing and new store opportunities while pursuing operational efficiencies [11] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment in Q4 performance but noted improvements in trends for the first quarter of fiscal 2025 [7][18] - There is cautious optimism regarding sales performance as warmer weather approaches, which may positively impact sales [45] - The company expects to operate without accessing its credit facility throughout fiscal 2025, provided that sales do not decline significantly [21][55] Other Important Information - Total capital expenditures in fiscal 2024 were $8.2 million, down from $14 million in fiscal 2023 [17] - The company anticipates a net loss per share in the range of $0.68 to $0.58 for the first quarter of fiscal 2025 [19] Q&A Session Summary Question: Impact of tariffs on the company - Management indicated that the tariff impact would be minor, affecting only one vendor for private label products [25] Question: Consumer impact from economic conditions - Management hopes that merchandising changes will help mitigate potential consumer headwinds [27] Question: Store openings and capital expenditures - The company plans to be opportunistic with store openings, having opened two profitable stores recently, but expects to close more unprofitable stores [31][32] Question: Commentary on Q4 comparable sales decline - Management noted that November was particularly weak, with a 21% decline, while December and January saw smaller declines [41] Question: Trends in February sales - February saw a 5.7% decline in comparable net sales, with a brief period of positive sales due to warmer weather [45] Question: Timing of merchandising changes - Management expects to see results from merchandising changes by July [50] Question: Inventory balance and credit facility usage - The company plans to maintain lower unit inventories throughout the year and does not expect to access the credit facility unless sales decline significantly [55]

Financial Data and Key Metrics Changes - Total net revenue for Q1 2025 was $34.3 million, down from $39.7 million in Q1 2024, reflecting a decline of approximately 11% [25] - Agribusiness revenue decreased to $32.9 million from $38.3 million year-over-year, a decline of about 14% [25] - Total costs and expenses decreased by 16% to $39.7 million compared to $47.5 million in the previous year [32] - Operating loss improved to $5.3 million from $7.7 million, a reduction of approximately 31% [32] - Net loss applicable to common stock was $3.2 million, compared to $3.7 million in Q1 2024 [32] - Adjusted EBITDA improved to a loss of $2.3 million from a loss of $4.8 million year-over-year [33] Business Line Data and Key Metrics Changes - Fresh packed lemon sales were $21.2 million, down from $23.9 million, with 1,147,000 cartons sold at an average price of $18.44 per carton compared to $21.06 in the prior year [27] - Avocado revenue was $162,000 in Q1 2025, a new revenue stream compared to no revenue in Q1 2024, with 73,000 pounds sold at an average price of $2.25 per pound [28] - Orange revenues increased to $1.6 million from $1.1 million, with 75,000 cartons sold at an average price of $20.91 per carton [28] - Specialty citrus and wine grape revenue decreased to $0.5 million from $1.1 million, with no wine grape revenue recorded in Q1 2025 [30] Market Data and Key Metrics Changes - The lemon market faced temporary oversupply, leading to downward pricing pressure, which is expected to persist through Q2 2025 [26] - The company anticipates a strengthening of the lemon business in the second half of the year due to seasonal pricing improvements and reduced imports from Spain [13] Company Strategy and Development Direction - The company is focusing on transforming its business model to an asset-lighter approach, optimizing revenue mix, and expanding avocado production [9][11] - Strategic investments in citrus and avocado markets are aimed at diversifying revenue streams and enhancing long-term operational and financial outlook [11][26] - The company plans to expand avocado production by 1,000 acres through fiscal year 2027 to meet consumer demand [18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the EBITDA outlook and the potential for additional asset monetization gains in fiscal year 2025 [38] - The company is confident in its ability to navigate market volatility and expects to receive $165 million from its joint ventures over the next six fiscal years [37] Other Important Information - The company successfully monetized water pumping rights for $1.5 million, contributing positively to its financial results [12][34] - A revised flood zone map approved by FEMA is expected to enhance interest in residential and commercial real estate in affected areas [20][21] Q&A Session Summary Question: Inquiry about Water right transaction volume - Management explained that the volume of 58 acre feet was based on opportunistic demand and benchmarked against local development rates [43][45] Question: Future water transactions and partnerships - Management indicated that both existing and new partners are being explored for future water monetization opportunities [47][48] Question: Expansion potential in avocado production - Management noted the feasibility of expanding avocado acreage by 250 to 500 additional acres, contingent on environmental conditions [51][53] Question: Market dynamics for avocado growth - Management discussed the limitations of nursery stock availability and the geographical constraints for avocado cultivation in California [59][58]

Financial Data and Key Metrics Changes - Revenue for 2024 was $25.2 million, up 57% from $16 million in 2023 [35] - Fourth quarter revenue was $7 million, marking a 36% increase over the same quarter last year [9] - Full year gross margins improved to 85% from 83% in the previous year [10] - Net loss for 2024 narrowed by 37% to $11.9 million compared to $18.8 million in 2023 [38] - Cash, cash equivalents, and marketable securities totaled approximately $12.2 million at year-end 2024, up from $10.6 million in 2023 [39] Business Line Data and Key Metrics Changes - Sales in the VA channel grew 85% to $17.8 million in 2024 from $9.6 million in 2023 [14] - Truvaga net sales reached $2.8 million in 2024, a 174% increase over 2023 [16] - TAC-STIM sales were $1.2 million for the full year, down from $1.7 million in the previous year [20] - U.S. prescription gammaCore channel recorded revenue of $1.5 million, down 15% from 2023 [22] Market Data and Key Metrics Changes - Approximately 30 million covered lives in the U.S. for the prescription headache business [12] - Revenue from channels outside the U.S. was flat at $1.9 million for 2024 [24] - The VA Hospital System remains the largest customer, with 170 facilities purchasing gammaCore products [15] Company Strategy and Development Direction - The company aims to become a leader in the bioelectronic health and wellness sector through acquisitions like NeuroMetrix [25] - Plans to leverage existing sales channels for new products, including Quell for fibromyalgia and Sparrow for opioid withdrawal [28][32] - Focus on expanding Truvaga's market presence through e-commerce and partnerships [49] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about long-term prospects, citing growth in prescription products and wellness offerings [42] - The company is aware of macroeconomic disruptions affecting VA hospital customers but has not seen direct impacts on business cadence [46] - Future growth is expected from prescription gammaCore sales and direct-to-consumer initiatives [118] Other Important Information - The company plans to maintain discipline around operating expenses while investing in growth [55] - The acquisition of NeuroMetrix is expected to close in Q2 2025, enhancing the product portfolio [26] - The company is exploring international expansion for Truvaga products [125] Q&A Session Summary Question: Plans for selling the Quell product post-acquisition - The company plans to integrate Quell into existing sales channels and provide training to the sales team after the acquisition closes [62][64] Question: Update on Joerns and its growth - The company acknowledges slower traction with Joerns but is seeing early signs of growth with more prescribers [80] Question: Comparison of Kaiser channel to VA system - The Kaiser channel is more challenging to penetrate but once established, it is expected to be a sticky business [89] Question: Future growth opportunities - The company sees potential in prescription gammaCore sales, direct-to-consumer growth, and new product acquisitions [118] Question: Impact of VA personnel reductions - No material impact observed yet, but the situation is being monitored closely [126] Question: Confidence in achieving mid-80s gross margin - The company expects to maintain mid-80s gross margins in 2025, primarily from existing products [129] Question: Plans for Truvaga sales growth - The company is focusing on omnichannel distribution, including e-commerce and influencer marketing [146]